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Abstract
Background: Ulcerative Colitis (UC) and Crohn’s Disease (CD) are two chronic Inflammatory Bowel Diseases (IBD) affecting
the intestinal mucosa. Current understanding of IBD pathogenesis points out the interplay of genetic events and
environmental cues in the dysregulated immune response. We hypothesized that dysregulated microRNA (miRNA)
expression may contribute to IBD pathogenesis. miRNAs are small, non-coding RNAs which prevent protein synthesis
through translational suppression or mRNAs degradation, and regulate several physiological processes.
Methodology/Findings: Expression of mature miRNAs was studied by Q-PCR in inactive colonic mucosa of patients with UC
(8), CD (8) and expressed relative to that observed in healthy controls (10). Only miRNAs with highly altered expression (.5
or ,0.2 -fold relative to control) were considered when Q-PCR data were analyzed. Two subsets of 14 (UC) and 23 (CD)
miRNAs with highly altered expression (5.2-.100 -fold and 0.05–0.19 -fold for over- and under- expression, respectively;
0.001,p#0.05) were identified in quiescent colonic mucosa, 8 being commonly dysregulated in non-inflamed UC and CD
(mir-26a,-29a,-29b,-30c,-126*,-127-3p,-196a,-324-3p). Several miRNA genes with dysregulated expression co-localize with
acknowledged IBD-susceptibility loci while others, (eg. clustered on 14q32.31), map on chromosomal regions not previously
recognized as IBD-susceptibility loci. In addition, in silico clustering analysis identified 5 miRNAs (mir-26a,-29b,-126*,-127-
3p,-324-3p) that share coordinated dysregulation of expression both in quiescent and in inflamed colonic mucosa of IBD
patients. Six miRNAs displayed significantly distinct alteration of expression in non-inflamed colonic biopsies of UC and CD
patients (mir-196b,-199a-3p,-199b-5p,-320a,-150,-223).
Conclusions/Significance: Our study supports miRNAs as crucial players in the onset and/or relapse of inflammation from
quiescent mucosal tissues in IBD patients. It allows speculating a role for miRNAs as contributors to IBD susceptibility and
suggests that some of the miRNA with altered expression in the quiescent mucosa of IBD patients may define miRNA
signatures for UC and CD and help develop new diagnostic biomarkers.
Citation: Fasseu M, Tre ´ton X, Guichard C, Pedruzzi E, Cazals-Hatem D, et al. (2010) Identification of Restricted Subsets of Mature microRNA Abnormally Expressed
in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease. PLoS ONE 5(10): e13160. doi:10.1371/journal.pone.0013160
Editor: Guillaume Dalmasso, Emory University, United States of America
Received June 21, 2010; Accepted September 5, 2010; Published October 5, 2010
Copyright:  2010 Fasseu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Institut National de la Sante et de la Recherche Medicale (Inserm) and in parts by grants from Association Francois Aupetit AFA, Assistance Publique-
Hopitaux de Paris, Ferring Laboratories, Ipsen Laboratories, Societe Nationale Francaise de Gastro-enterologie (SNFGE), Association Francaise pour l’etude du foie
(AFEF), and Programme National de Recherche en Hepato-Gastroenterologie. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: Funding by Ipsen Laboratories was only a small part of the doctoral fellowships dedicated to Xavier Treton. It did not interfere with the
study reported in the manuscript and does not alter the authors’ adherence to all the PLoS ONE policies.
* E-mail: andre.groyer@inserm.fr
. These authors contributed equally to this work.
" These authors also contributed equally to this work.
Introduction
Ulcerative Colitis (UC) and Crohn’s Disease (CD) are two
subphenotypes of inflammatory bowel disease (IBD) affecting the
intestinal mucosa. UC and CD share similarities such as a chronic
relapsing-remitting course and common extra-intestinal manifes-
tations. However, several differences in localization (any part of
the gastrointestinal tract -CD- or restricted to the colon -UC),
endoscopic appearance and histology support differences in
underlying physiopathology.
The current understanding of IBD pathogenesis points out the inter-
play of genetic, epigenetic and environmental factors in the dysregulated
immune response of the intestinal mucosa [1–3] where inappropriate
control of innate and acquired immunity plays a major role [4].
Long term follow-up stressed that basal colonic lesions extend
progressively in more than 50% of UC patients [5]. In CD
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tissues at the time of ileo-colonic resection was reported to reach
73% at one year [6]. These observations suggest that quiescent
mucosa of IBD patients display increased susceptibility to
inflammation. In this connection, animals models (mice carrying
intestinal epithelial cell-specific invalidation of genes involved in
the unfolded protein response -XBP1, X-box Protein 1- or
essential for embryonic development of the colon -HNF4, Hepatic
Nuclear Factor 4) support the notion that epithelial cell
dysfunction in the quiescent mucosa can trigger intestinal
inflammation [7–8]. However the early epithelial disorders that,
in pre-inflammatory states, confer susceptibility to uncontrolled
mucosal inflammation remain poorly understood.
Strong evidence supports UC and CD as complex genetic
disorders with significant overlap and mandates systematic
approaches to identify causal molecular events. First, Genome
Wide Association Scans (GWAS) [9–19] and candidate gene
approach [20–25] led to the identification of more than 30
susceptibility loci for CD and UC and identified ‘‘IBD-specific’’
gene variants within these loci (eg. CARD15, TNFSF15, IL23R,
ATG16L1, IRGM, PTPN2). Otherwise, genome-wide arrays and
subtractive hybridization studies identified hundreds of mRNAs
with altered expression in non-inflamed [26,27] and in inflamed
[28–32] colonic biopsies obtained from UC and CD patients. This
provided valuable insights into dysregulated gene expression
associated with IBD. In this connection, we hypothesized that
dysregulated microRNA (miRNA) gene expression and/or pri-/
pre- miRNA maturation may contribute to IBD pathogenesis.
miRNAs are small (,18–24 nt), non-coding RNAs which, by
base-pairing to complementary sequences in the 39-UTR of
selected mRNA targets, prevent protein synthesis either by
translational suppression [33,34] or by degradation of their target
mRNAs [35,36]. miRNAs are regulators of early development, cell
fate determination, differentiation, proliferation, apoptosis [37–39]
and dysregulation of their expression has been involved in various
human diseases such as cancer [40–44], developmental abnor-
malities [45], muscular disorders [46] and inflammatory diseases
[47–51].
In the present paper, our first objective was to pinpoint
alterations in the pattern of miRNA expression in the non-
inflamed colonic mucosa of UC and CD patients relative to that of
healthy subjects. Indeed, such altered miRNA expression in the
quiescent colonic mucosa of IBD patients may account for
epithelial dysfunction in the absence of epithelial damage (eg.
ulcerations) and sensitize the mucosa to severe inflammation and
infiltration of immune cells. Our second objective was to search
whether dysregulated expression of several miRNAs may be
coordinated and thus contribute to IBD susceptibility.
Results
In a first series of experiments, miRNA expression was
quantified in right and left colon from healthy control subjects.
Measuring the abundance of 321 mature human miRNA
transcripts by real-time Q-PCR, preliminary analysis (2
2DCT)
showed that right and left colon displayed similar patterns of
miRNA expression, as exemplified for a subset of miRNAs in
Table S1.
In a second series of experiments, miRNA expression was
measured by real-time Q-PCR in biopsies from UC and CD
patients (Table 1; quiescent and inflamed mucosal tissues, Figure
S1). Overall, miRNA expression varied continuously from 211.06
to +20.31 -fold (quiescent and inflamed CD biopsies) and from
27.50 to +18.34 -fold (quiescent and inflamed UC biopsies) when
compared to healthy control subjects. However, a careful
inspection of the data showed that even under our strictly
controlled (i) biopsy selection (Figure S2), (ii) RT and (iii) Q-PCR
conditions, miRNA expression levels were variable among patients
(Figure S3). Thus, in order to avoid false/erroneous classification
of miRNAs as up- and down- regulated in mucosal biopsies of IBD
patients, only miRNAs with alterations of expression that fitted
stringent thresholds (2
2DDCT.5-fold and 2
2DDCT,0.2-fold,
respectively) were considered.
miRNA expression is altered in both UC and CD
In order to check for specific modifications that may account for
epithelial cell dysfunction in the quiescent colonic mucosa of IBD
patients, we focused on biopsies scored grades 0 and 1 (both grades
were observed in healthy controls and in quiescent UC and CD
mucosa; Table S2). However, grades 2–4 (inflamed mucosa; see
Figure S1) were also studied for comparison of both stages of the
diseases.
According to our stringent criteria for the selection of miRNAs
with altered expression, up- and down- regulations were balanced
in UC (45.47% and 54.5%, respectively), whereas up-regulation
was predominant (88.2%) in CD.
UC. 173 miRNAs were expressed above the level of detection
(CT,35). Of the 22 miRNAs that fit our stringent criteria, only 14
(7 up- and 7 down- regulated) exhibited significant differential
expression when non-inflamed UC and healthy control tissues
were compared (0.001,p,0.05; non parametric Mann-Whitney
test), (Table S3, Figure 1A). With respect to cut-off values and
statistical significance the expression of 9 miRNAs was dysregu-
lated in both quiescent and inflamed UC mucosa and that of 1
miRNAs was specifically dysregulated in quiescent UC mucosa
(mir-196a).
CD. 204 miRNAs were expressed above the level of detection.
Of the 33 miRNAs that fit our stringent criteria, only 23 (all up-
regulated) exhibited significant differential expression when non-
inflamed CD and healthy control tissues were compared
Table 1. Characteristics of patients with CD or UC.
Ulcerative Colitis Cronh’s Disease
Nu of patients 8 8
Male/Female 5/3 4/4
Age (* y)
Mean 45.9 37.6
Range 33–57 20–58
Disease duration (y)
Mean 10.5 8.8
Range 1–21 0.5–23
# Medications (%)
5 ASA 6 (75) 2 (25)
CS - 2 (25)
AZA 1 (13) 2 (25)
MTX, IFX - 1 (13)
CS, 5 ASA 1 (13) -
None - 1 (13)
*y, years;
#Medications : CS: steroids/5 ASA: 5 aminosalicylates/AZA: azathioprine/IFX:
infliximab/MTX: methotrexate.
doi:10.1371/journal.pone.0013160.t001
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Figure 1B). With respect to cut-off values and statistical
significance the expression of 18 miRNAs were dysregulated in
both quiescent and inflamed CD mucosa and that of 4 miRNAs
were specifically dysregulated in quiescent CD mucosa (mir-9*,
mir-30a*, mir-30c, mir-223).
Finally, taking into account cut-off values and statistical
significance, we also noticed alterations in miRNA expression
specific to inflamed UC or CD tissues (4 and 5 miRNAs,
respectively) (Figure 1A, B).
Common and specific alterations in miRNA expression in
UC and CD
With respect to cut-off values and statistical significance 8
miRNAs shared common altered expression in non-inflamed CD
and in non-inflamed UC (Figure 1C, Table S5), of which 6 (all but
mir-30c, and mir-196a) were also overexpressed both in inflamed
UC and in inflamed CD biopsies.
On the other hand, the expression of 6 miRNAs was statistically
different in non-inflamed colonic biopsies of UC and CD patients
(mir-150, p=0.0273; mir-196b, p=0.0472; mir-199a-3p,
p=0.0472; mir-199b-5p, p=0.0283; mir-223, p=0.0357 and
mir-320a, p=0.0163; non-parametric Mann-Whitney test)
(Figure 2). These miRNAs, and an additional selection of 9
miRNAs (selected in an unsupervised manner using the Gene-
Pattern ‘‘ComparativeMarkerSelection’’ module) (Owing to patent
pending the identity of these miRNA is not disclosed in the
manuscript) were tested for their ability to discriminate between
UC and CD. Classification was performed with a supervised
algorithm (GenePattern ‘‘KNNXValidation’’ module). Based on
the clinical classification of our panel of patients as UC or CD, the
selection of 15 miRNAs was able to predict 15/16 patients in their
true class (Table 2).
Altogether, these data unambiguously show that altered miRNA
expression pre-exists in non-inflamed UC and CD mucosa.
Concerted regulation of miRNA expression in UC and CD
We then sought whether the altered levels of miRNA noticed in
both quiescent UC and CD colonic mucosa could be accounted
for by coordinated regulation(s) of miRNA expression. In silico
clustering was achieved in an unsupervised manner using a K-
Means algorithm, the expression data being partitioned into 20
distinct computational clusters. Interestingly, 7/8 miRNAs
overexpressed both in non-inflamed UC and CD tissues (mir-
26a, mir-29a, mir-29b, mir-30c, mir-126*, mir-127-3p, mir-324-
3p), localized on different chromosomes, were assigned to a single
computational cluster (cluster #7) when examining UC data, and
to two such clusters (cluster #7: mir-26a, mir-30c, mir-127-3p,
mir-324-3p and cluster #13: mir-29a, mir-29b, mir-126*) when
CD data were inspected (Table 3). Moreover, five of these
miRNAs (mir-26a, mir-29b, mir-126*, mir-127-3p, mir-324-3p)
were also assigned to a single computational cluster when inflamed
UC (cluster #7) and CD (cluster #13) data were classified. This
suggested common regulation of expression for mir-26a, mir-29b,
mir-126*, mir-127-3p and mir-324-3p.
Chromosomal localization of miRNA genes with altered
expression
The chromosomal distribution of miRNA genes with altered
expression in UC and CD mucosa was not even. Indeed, 9
chromosomes (1, 5, 9, 11, 14, 15, 17, 19 and X) housed $4 and up
to 12 miRNA genes with dysregulated expression (overall: ,70%
Figure 1. Disease- and stage- specific alterations of miRNA expression. miRNA expression was measured in non-inflamed and inflamed UC
and CD tissues and computed vs. that measured in healthy controls. The total numbers of miRNAs that were underexpressed and overexpressed in
non-inflamed (dark-colored ovals) or inflamed (light-colored ovals) IBD tissues, as well as those that were commonly altered in both states of the
disease (intersect between light and dark-colored ovals) were determined. UC (A) or CD (B) tissues were considered independently. (C) miRNAs that
were underexpressed and overexpressed in non-inflamed UC (dark-blue) or non-inflamed CD (dark-red), as well as those that were commonly altered
in both diseases (intersect between ovals) were determined. Underexpressed miRNAs are underlined. Bolded characters, miRNA with statistically
significant dysregulation of expression relative to healthy controls (p#0.05).
doi:10.1371/journal.pone.0013160.g001
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loci where miRNA genes with dysregulated expression are
localized encompass either one, two (miRNA duplexes) or more
(miRNA clusters) distinct miRNA genes.
Interestingly, it could be observed that several miRNAs mapped
within acknowledged IBD susceptibility loci (IBD-2, 3, 5 and 6), or
colocalized with genetic variations identified in several GWAS
studies that (i) account for part of the overall genetic susceptibility
to CD and (ii) contribute to UC pathogenesis (Figure S5, Table
S7). None mapped with IBD susceptibility loci 1, 4, 7, 8 and 9.
Otherwise, one chromosomal miRNA cluster (on chromosome
14q32.31) and several miRNA duplexes (6q13, 7q32.3, 9q34.11–
q34.3, 15q26.1; 17p13.1–p13.3, 22q11.21, Xq26.2) were identi-
fied that map on chromosomal regions that have not been
previously reported as IBD-susceptibility loci (Figure S5, Table 4).
Interestingly, in the majority of loci, alterations of miRNA
expression were observed in quiescent UC and CD tissues.
Alteration of miRNA expression: in silico characterization
of target transcripts
Identification of a subset of 8 miRNAs that share common
regulated overexpression in both UC and CD (see Table S5) could
represent the first step towards the identification of regulatory
networks, the dysregulation of which could be involved in the
pathophysiology of IBD. In silico, 4094 genes (372 strictly down-
regulated genes) stand as putative targets for these miRNAs.
Exploring the molecular functions associated to these gene
products using The Gene Ontology, GeneCards and GeneNote
data bases, we found associations to several biological processes
(Figure 3). These include (i) cell proliferation (Cyclins D1, D2 and
E1, PCNA, CDKs 6 and 8, GADD45A, RB1), (ii) apoptosis
(BCL2, Caspase 2, C/EBP b,c, DAPK, FOXO3, PTEN), (iii)
autophagy (ATG 4a, 5 and 9a, Beclin-1, CDKN1B, IFNc), (iv)
extracellular matrix organization, cell adhesion and cell surface
marker gene expression (COL(1,11,12,15,16)A1, Integrin-a1,2,3,5,
Figure 2. miRNAs with differentially altered expression in non-inflamed UC and CD tissues : Box-whisker plot analysis. miRNA
expression was measured in non-inflamed colonic mucosa obtained from UC and CD patients (8 patients/IBD) and computed vs. that measured in
healthy controls. Data corresponding to 6 miRNAs (mir-150, mir-196b, mir-199a-3p, mir-199b-5p, mir-223 and mir-320a) with statistically different
alteration of expression in UC and CD mucosal tissues are presented as box-whisker plots [78] (box, 25–75%; whisker, 10–90%; line, median); p,0.05.
doi:10.1371/journal.pone.0013160.g002
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oxidative stress (GPX4, OXR1, OSXR1), (vi) the unfolded protein
response (HSPA5, HSPA2, SERP1, XBP-1, EIF2AK3, ETF1) (vii)
innate and adaptive immunity (IL1A, IL10, IL1R1, IL6R,
IRAK2, p40
phox, TLR10, CXCL2, 12 and 14, CXCR4, NFATC3
and C4, PREX1). In addition, several of these genes are
acknowledged IBD-susceptibility genes or are localized at
replicated risk loci identified by GWAS (eg. ATG16L1, IL10,
IL12B, JAK2, ARPC2, PTGER4, ZNF365, NKX2-3, PTPN2,
PTPN22, C11orf30, ORMDL3, STAT3 (Table S8).
Discussion
In the present study, we have addressed the question of whether
altered miRNA expression in quiescent UC and CD mucosa may
be relevant to IBD pathogenesis. Our data allowed two major
conclusions.
First. Alteration of miRNA expression was not confined to
inflamed (grades 2–4), but preexisted in non-inflamed (grades 0
and 1) mucosa. Applying strictly controlled RT and real-time Q-
PCR protocols and stringent cut-off values (.5-fold or ,0.2-fold
vs. healthy individuals), we identified 14 and 23 miRNAs with
dysregulated expression in non-inflamed UC and CD biopsies,
respectively, of which 8 were similarly dysregulated both in non-
inflamed UC and CD biopsies. Our observation that mir-26a and
29a are up-regulated in quiescent UC mucosa has also been
reported by Wu et al. [51]. In contrast, the other miRNAs (9/10,
mir-629 was not tested in our screen) which were found to be up-
(eg. mir-21, mir-126 and Let-7f) or down- (eg. mir-19b) regulated in
[51] displayed only slight alterations in relative expression that did
not match the stringent selection criteria we applied in our study.
This suggests (i) that the discrepancies between both studies may
Table 2. Achievement of patient’s class (UC or CD) prediction using the selection of 15 miRNAs.
Patient True Class Predicted Class Confidence Correct ?
Initial Diagnostic
Reassessment After
Clinical Follow-up
Relative to Initial
Diagnostic
After Clinical Follow-up/
Reassessment
CD_Quiescent_28 Cd Not modified Uc 1 false
CD_Quiescent_102 Cd Not modified Cd 1 true
CD_Quiescent_111 Cd Not modified Cd 1 true
CD_Quiescent_120 Cd Not modified Cd 1 true
CD_Quiescent_130 Cd Not modified Cd 0,7894 true
CD_Quiescent_137 Cd Not modified Cd 1 true
CD_Quiescent_158 Cd Not modified Cd 1 true
CD_Quiescent_160 Cd Not modified Cd 1 true
UC_Quiescent_107 Uc Not modified Uc 1 true
UC_Quiescent_125 Uc Not modified Uc 0,8144 true
UC_Quiescent_121 Uc Not modified Uc 1 true
UC_Quiescent_114 Uc Not modified Uc 0,5339 true
UC_Quiescent_109 Uc Not modified Uc 0,5508 true
UC_Quiescent_13 Uc Cd Cd 0,6229 false true
UC_Quiescent_15 Uc Not modified Uc 0,6415 true
UC_Quiescent_132 Uc Not modified Uc 0,5176 true
The 6 miRNAs that displayed significantly distinct alteration of expression in non-inflamed colonic biopsies of UC and CD patients and 9 additional miRNAs, which were
selected in an unsupervised manner making use of the GenePattern ‘‘ComparativeMarkerSelection’’ module, were tested for their putative use as ‘‘biomarkers’’. The test
was carried out using the ‘‘KNNXValidation’’ module computed on line from the GenePattern server. Of note, patient ‘‘UC_Quiescent_13’’, initially classified as UC on
the basis of clinical criteria, was predicted as CD using our selection of 15 miRNAs. Interestingly its clinical follow-up for several years led to the reassessment of its
clinical classification as CD.
doi:10.1371/journal.pone.0013160.t002
Table 3. Concerted regulation of expression of miRNAs in
non-inflamed and inflamed CD and UC tissues.
Overexpressed miRNA
UC CD
Non-inflamed Inflamed Non-inflamed Inflamed
Cluster #7 : Cluster #7 : Cluster #7 : Cluster #13 :
mir-15a mir-7 mir-7 mir-26a
mir-26a mir-26a mir-26a mir-29b
mir-29a mir-29a mir-30b mir-126*
mir-29b mir-29b mir-30c mir-155
mir-30c mir-31 mir-127-3p mir-127-3p
mir-126* mir-126* mir-155 mir-185
mir-127-3p mir-127-3p mir-223 mir-196a
mir-324-3p mir-135b mir-324-3p mir-324-3p
mir-324-3p mir-378
Cluster #13 :
mir-29a
mir-29b
mir-126*
mir-196a
Alterations in miRNA expression (8 UC, 8 CD patients) were clustered using a K-
Means algorithm (computed on-line on the GenePattern server), independently
in each IBD and for each state of the disease. Clusters that encompass several
miRNAs with similarly up-regulated expression are highlighted (bold
characters).
doi:10.1371/journal.pone.0013160.t003
miRNA Expression in IBD
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13160be explained either by the differential sensitivity of the methods
used for initial screening (microarray vs. real-time Q-PCR) and/or
rather by the drastic cut-off value (.5-fold or ,0.2-fold) we used
to state altered miRNA expression in the present study and (ii) that
the overlap in the alteration of miRNA expression observed in our
study and in that reported by Wu et al. [51] may not have occurred
only by chance. As far as we are aware, alteration of miRNA
expression in non-inflamed CD colonic biopsies has not yet been
reported.
Importantly, despite (i) the choice of a drastic cut-off that takes
into account the variability in miRNA expression between IBD
patients and (ii) the limited number of subjects kept for analysis in
the present study, we could select miRNAs highly and significantly
dysregulated in IBD relative to healthy controls. Interestingly,
comparison of non-inflamed to inflamed tissues showed significant
overlap in the alteration pattern of miRNA expression both in CD
patients (this study) and UC (this study, [51]).
Altogether, these results support the notion that dysregulation of
miRNA expression pre-exists in the quiescent colonic mucosa of
UC and CD patients and may play a key role in the sensitization of
the quiescent mucosa to environmental factors and/or to IBD
inducers (ie. commensal flora), and in fine the onset and/or relapse
of inflammation. Furthermore, they suggest that quiescent UC and
CD mucosa already has distinct miRNA signatures which are not
associated with significant variations in cellular contexts. Indeed,
the quiescent colonic mucosa of IBD patients and that of healthy
subjects were almost similar (grades 0 or 1 in both cases).
Since significant overlap was observed in the alteration of
miRNA expression in quiescent UC and CD mucosa, our results
also imply that several common molecular mechanisms may
underlie the UC and CD pathogenic processes. Furthermore,
alteration of miRNA expression in quiescent IBD tissues is
consistent with the notion that genetic variants that result in
differential gene expression (eg. that of regulatory molecules such as
miRNAs) as well as mutations in the open reading frame are
expected to contribute to multifaceted diseases.
In this connection, one major drawback in investigating the
dysregulation of miRNAs and of protein-coding genes expression
in IBD tissues is related to cell type variations between samples (eg.
inflamed vs. quiescent mucosa and normal healthy tissue). Indeed,
inflamed mucosal tissue is characterized by a decreased number of
epithelial cells, concomitant with an increased infiltration of
inflammatory cells. This bias was taken into account in some
genome wide cDNA microarray studies [26] but not in others
[31]. For instance, decreased MICA (a gene expressed in intestinal
epithelial cells) transcript expression was reported in inflamed CD
[31] whereas flow cytometry and immuno-histochemistry identi-
fied strong MICA overexpression in intestinal epithelial cells of
macroscopically involved areas of CD patients [52]. Similarly, it
could be anticipated that the decreased level of mir-192 expression
in inflamed mucosa of UC patients [51] may depend on cell-type
heterogeneity between non-inflamed and inflamed mucosal tissues
rather than on decreased gene expression (of note, in our study the
slight decrease in mir-192 expression did not match our selection
criteria in inflamed UC mucosa). Thus, the increase in MIP2a
expression observed in [51] could be miRNA-independent and
accounted for by increased TNFa secretion by immune infiltrating
cells.
Finally, starting with a wide screen of 321 miRNAs, we could
define (i) a selection of 8 miRNAs relevant in defining quiescent
IBD vs. healthy mucosa and (ii) a distinct subset of 15 miRNAs
(Patent pending) that allows discriminating between non-inflamed
Table 4. Compilation of the sub-chromosomal regions where two or more miRNA genes with altered expression colocalize.
Chromsome miRNA Alteration of Expression Duplex/Cluster
Gene_Id Locus IBD_Type Disease state +/2
6 30c-2 6q13 CD/UC Quiescent/Quiescent + miRNA Duplex
30a* 6q13 CD Quiescent +
7 29a 7q.32.3 CD/UC Both/Both + miRNA Duplex
29b-2 7q.32.3 CD/UC +
9 199b-5p 9q34.11 UC Both 2 miRNA Duplex
126 9q34.3 CD Inflamed +
126* 9q34.3 CD/UC Both/Both +
14 127-3p 14q32.31 CD/UC Both/Both + miRNA Cluster
370 14q32.31 UC Both 2
382 14q32.31 UC Inflamed +
15 7-2 15q26.1 UC Inflamed + miRNA Duplex
9-3 15q26.1 CD Inflamed +
17 22 17p13.3 CD Both + miRNA Duplex
324-3p 17p13.1 CD/UC Both/Both +
22 185 22q11.21 CD Both + miRNA Duplex
130b 22q11.21 CD Inflamed 2
X 106a Xq26.2 CD Both + miRNA Duplex
20b Xq26.2 CD Inflamed +
Compilation of chromosomes and bands where colocalize 2 (miRNA Duplex) or more (miRNA Cluster) miRNA genes with altered expression relative to healthy controls
in UC or CD tissues. Gene_Id, miRNA gene identification number; Locus, chromosomal band where the miRNA gene is localized; Quiescent, non-inflamed; Both, non-
inflamed and inflamed; +/2, +: overexpression; 2: underexpression.
doi:10.1371/journal.pone.0013160.t004
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relevant for UC and CD. Indeed on the basis of our panel of 16
patients, this selection of 15 miRNAs was able to predict 15/16
patients (94%) as UC or CD correctly. Such biomarkers may
prove helpful as diagnostic tools of minimal invasivity (eg. for
pediatric patients, incomplete colonoscopy) and as guidelines for
surgical decisions. It can also be anticipated that miRNA
signatures could be associated with different IBD profiles as
prognostic biomarkers. This is out of the scope of the present study
and deserves further studies on a larger cohort of patients.
Second. miRNAs play a major role in regulating coding-gene
expression at the transcript and/or translational levels [34,36]. In
this connection, we would like to emphasize that our study is the
first one that reports the mapping of several miRNA genes with
altered expression in quiescent UC and CD mucosa (i) at
acknowledged IBD loci [53–55] or (ii) at loci conclusively
associated with CD [11,16] } or UC [12,13,19] by GWAS
studies. In this connection, we should like to emphasize that the
co-localization of miRNA genes with dyregulated expression at
chromosomal loci associated with IBD susceptibility does not
occur only by chance. Indeed, our computations show that 1
miRNA gene (out of 321 tested) would be expected to be localized
by chance in the vicinity of the 50 loci reported in [11,12,16–19]
where 14 miRNA genes (14-fold more) with altered expression in
quiescent UC and CD tissues map. In addition, even if 8 miRNA
genes could map by chance within IBD susceptibility loci 1, 4, 7, 8
and 9, no miRNA genes with altered expression in quiescent UC
and CD tissues were localized in these chromosomal regions
(although they encompass a total of 18 miRNA genes, the
expression of which is not altered in IBD).
On this basis, we speculate that in addition to mutational events,
IBD susceptibility might result from dysregulated miRNA
expression in intestinal mucosa and to subsequent alteration of
miRNA-dependent regulation of gene expression; consistent with
the notion that not only allele variation, but also the alteration of
regulatory processes that result in differential gene expression may
contribute to multifaceted diseases.
Furthermore, our study characterizes band 14q32.31 as a
cluster of 3 miRNA genes with altered expression in IBD. With the
exception of mir-382, these miRNAs display altered expression in
quiescent UC (mir-127-3p, mir-370) or in quiescent CD (mir-127-
3p) mucosa. These miRNA genes are intergenic and constitute at
least two distinct transcription units (mir-127 and mir-370).
Alteration of miRNA expression within this sub-chromosomal
region does not result from the overall chromosomal environment
since (i) only the expression of 3 (UC) and 1 (CD) miRNAs was
altered out of 38 localized within a DNA stretch of 44.74 kbp at
14q32.31, (ii) expression was either increased (mir-127-3p, CD/
UC; mir-382, UC) or decreased (mir-370, UC) and (iii) expression
was altered either in non-inflamed or in inflamed or in both states
of the diseases. We speculate band 14q32.31 may represent a new,
yet undefined IBD-susceptibility locus; this remains to be
established and will be the subject of future studies.
Finally, the tight coordinated regulation of mir-26a, mir-29b,
mir-126*, mir-127-3p and mir-324-3p (which genes are wide-
spread on several chromosomes) in non-inflamed UC and CD
Figure 3. Alteration of miRNA expression in the colonic mucosa of UC and CD patients: in silico characterization of target
transcripts. The exhaustive list of genes which are putatively targeted by the subset of 8 miRNAs that share common dysregulated expression both
in quiescent UC and in quiescent CD was downloaded from the PITA catalog of predicted human microRNA targets (http://genie.weizmann.ac.il/
pubs/mir07/mir07_data.html). The algorithm makes use of the parameter-free model for miRNA-target interaction described by Kertesz et al. [75]. The
total number of genes involved in each single biological process is computed. Strict down regulation (light purple) stands for genes, the 39-UTR of
which interacts only with up-regulated miRNA(s).
doi:10.1371/journal.pone.0013160.g003
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contribute to the physiopathology of IBD. Interestingly, such
concerted regulation of expression correlates with related
biological functions. For instance, these miRNAs have been
demonstrated to play roles either in cell cycle regulation, or in
tumorigenesis in a broad spectrum of solid tumors (mir-26a, mir-
29b, mir-127-3p and mir-324) [56–61], in the regulation of
epithelial-mesenchymal transition and invasiveness (mir-126*)
[62,63] or in the control of apoptosis (mir-29b and mir-126*)
[64,65], in line with the higher than spontaneous occurrence of
colorectal cancer (5-10%) in IBD patients. Of note, a recent study
has reported that the mir-29 family of miRNAs regulates intestinal
membrane permeability [66]. This observation should be
connected with the increased gut permeability observed in IBD
patients [67].
In silico studies emphasized that the transcripts targeted by the 8
miRNAs which share common overexpression in the quiescent
colonic mucosa of both UC and CD patients correspond to genes
that are involved/implicated in several cellular processes (eg.
proliferation, apoptosis, autophagy, extracellular matrix organiza-
tion, cell surface marker gene expression, oxidative stress, unfolded
protein response, innate and adaptive immunity). Several of these
genes stand as acknowledged IBD susceptibility genes or as genes
of interest localized at convincingly replicated risk loci identified
by GWAS (eg. ATG16L1, IL10, IL12B, JAK2, ARPC2, PTGER4,
ZNF365, NKX2-3, PTPN2, PTPN22, C11orf30, ORMDL3,
STAT3). However, an exhaustive identification of the genes
targeted by UC- and/or CD- associated miRNAs (eg. common to
or distinct between UC and CD), the demonstration of their actual
regulation by miRNAs and the investigation of their influence on
intestinal inflammation in experimental models of colitis is far
beyond the scope of this paper and will be the subject of future
studies.
Our study supports miRNAs as crucial players in the onset and/
or relapse of inflammation from quiescent mucosal tissues in UC
and CD patients. It further highlights their putative role as
contributors to IBD susceptibility and thus will help unravel the
mechanisms (either distinct or shared between UC and CD)
involved in relapsing (eg. identification of key targets and of gene
networks). Finally, they may help develop new biomarkers to
distinguish UC and CD at early stages.
Materials and Methods
IBD patients and controls
Colonic pinch biopsies were obtained in the course of
endoscopical examination of patients with mild to severe CD
and UC and of healthy control subjects undergoing screening
colonoscopies (Table S2 for clinical details). Colonic biopsies were
punctured from 24 CD, 18 UC and 19 healthy controls (see Figure
S2). However, for the reasons outlined below (see paragraphs
‘‘Histopathological analyses’’ and ‘‘RNA isolation’’) and in Figure
S2, the biopsies collected from some patients were not included in
the study. Overall, expression of mature miRNAs was studied in
inactive colonic mucosa of 8 patients with UC, 8 patients with CD
and in 10 healthy control mucosa.
The diagnosis of UC and CD adhered to the criteria given by
Lennard-Jones [68]. Clinical disease activity for CD and UC was
assessed according to the Harvey-Bradshaw [69] and to the Colitis
Activity (CAI) [70] indexes, respectively. In each IBD patient,
endoscopically non-inflamed and inflamed areas of colonic tissue
were punctured (5 biopsies/area). Non-inflamed and inflamed
areas for biopsy collection were separated by more than 20 cm
along the colon. Three biopsies from each area were allocated for
immediate RNAlater
TM immersion then snap frozen and stored in
liquid nitrogen, and two were set apart for histopathological
examination. In healthy controls, 5 biopsies were punctured both
in right and left colon and processed as above. The protocol was
approved by the local Ethic Committee (Comite ´ de Protection des
Personnes -CPP- Ile de France IV nu2009/17 and AFFSSAPS
D91534-80) and written informed consent was obtained from all
patients.
Histopathological analyses
Biopsies were routinely stained with haematoxylin and eosin.
Histological assessments of mucosal damage and inflammatory
cells infiltration were graded by the same expert gastrointestinal
pathologist (DCH) using a score previously validated to charac-
terize the colonic involvement of both UC and CD [71]. Grades
were as follows: 0, no evidence of inflammation (normal mucosa);
1, oedema and mild infiltration in the lamina propria; 2, crypt
abscess and inflammation in the lamina propria; 3, severe
inflammation with destructive crypt abscess and 4, severe
inflammation with active ulceration. Grades 0–1 were considered
as quiescent (or non-inflamed) mucosa. Grades 2–4 corresponded
to various degrees of inflammation of the mucosa and were
considered as active disease (Figure S1). Alterations in miRNA
expression were studied following this histological dichotomy (0–1
vs. 2–4). IBD patients selected for miRNA analysis had both
histologically assessed quiescent and inflammatory samples. 7 CD
patients and 3 UC patients were excluded because their
endoscopically quiescent colonic mucosa was classified as
histologically active. 1 control patient with lymphocytic colitis
was excluded (Figure S2).
RNA Isolation
Total RNA was extracted with TRIzolH Reagent (Invitrogen)
then quantified using a ND-1000 NanoDrop spectrophotometer
(NanoDrop Technologies) and purity/integrity was assessed using
disposable RNA chips (Agilent RNA 6000 Nano LabChip kit) and
an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbrunn,
Germany). Only RNA preparations with RIN$7 were further
processed for analysis of miRNA expression. Nine CD, 7 UC and
8 controls with RNA preparations of insufficient purity (RIN,7)
were excluded. Finally 8 CD, 8 UC and 10 controls with stringent
homogeneity in histological assessment and RNA quality were
selected for analysis (Figure S2).
Reverse-Transcription and Real-Time Q-PCR
The Human Early Access Release Kit (based on miRBase v 9.2;
TaqManH MicroRNA Assay; Applied Biosystems) designed to
quantify 321 mature human miRNAs was used. cDNA was
generated from 10 ng of total RNA using miRNA-specific stem-
loop RT primers. Real-Time Q-PCR assays were performed
according to the manufacturer’s instructions using aliquots of
cDNA equivalent to ,1.3 ng of total RNA and were run in a
Light Cycler 480 (Roche Diagnostics).
Normalization of Real-Time Q-PCR results. Several
RNAs (U6, U24, U48 and S18) were tested as putative standards
and U6 (an ubiquitous small nuclear RNA) (Primer for U6 were
included in the TaqManH MicroRNA Assay) was found the most
reliable. Expression of miRNAs was computed relative to that of
U6 and a comparative threshold cycle method (2
2DDCT) [72] was
used to compare non-inflamed and inflamed IBD tissues with
healthy controls. Since the abundance of mature miRNA
transcripts was expressed relative to that of the reference gene
U6, we have checked that PCR efficiencies were identical for test
miRNA Expression in IBD
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be accurate (see the MIQE guidelines; [73]).
CT, the fractional cycle number at which the amount of
amplified target reaches a fixed threshold, was determined (default
threshold settings were used in all instances). The cycle number
above which the CT was considered as a false positive (cycle cut-
off point) was set up at 35, as already argued in the literature
dealing with limits of detection in Real-Time Quantitative- RT-
PCR [74] ( reviewed in [73]). 2DDCT was calculated as follows:
{DDCT~{(CTIBD{DCThealthycontrol)
where
DCThealthcontrol~(CThealthycontrol{CTU6)
And
DCTIBD~(CTIBD{CTU6)
Determination of cut-off values for miRNA over- and
under- expression. Relative miRNA expressions (2
2DDCT) were
computed as their log transformed (106log10) values (after such
computation up- and down- regulations were expressed as positive
and negative values, respectively), and their means and standard
deviations (SDmiRNA) were calculated independently for every
miRNA, in each IBD at each stage of the disease. Box-whisker
plots analysis of SDmiRNA pointed highly dispersed values among
patients (Figure S3). Overall, when the data gathered from the two
series of patients were considered (8 UC, 8 CD; non-inflamed and
inflamed areas of colonic tissues), a mean value of 6.361.4
(meanDisp 6 SDDisp) was calculated for the SDmiRNA values. Given
such variation in relative miRNA expression, only those with
mean 106log102
2DDCT.7 and ,27( 6|meanDisp+0.5 SDDisp|)
were considered as up- (2
2DDCT.5-fold) and down-
(2
2DDCT,0.2-fold) regulated relative to healthy.
In silico prediction of miRNA targets
Exhaustive human miRNA targets were predicted using a
parameter-free model for miRNA-target interaction. This model
computes the difference between the free energy gained from the
formation of the miRNA-target duplex (DGduplex) and the
energetic cost of unpairing the target (and proximal flanking
sequences) to make it accessible to the miRNA (DGopen) [75].
We made use of the PITA catalog of predicted human
microRNA targets (http://genie.weizmann.ac.il/pubs/mir07/
mir07_data.html). The seed parameter settings described in
Kertesz et al. [75] were followed: seeds of 8 bp in length, beginning
at position 2 of the miRNA were chosen, seed conservation being
set at 0.9. No mismatches or loops were allowed, but a single G:U
wobble was permitted. In genes missing a 39 UTR annotation,
800 bp downstream of the annotated end of the coding sequence
were used as the predicted 39 UTR. Flanks of 3 and 15 bp
upstream and downstream the miRNA target, respectively, were
considered in the computation of DGopen.
In some instances (mir-126*) predictions from the miRBase
database (miRBase Targets Release Version v5; http://microrna.
sanger.ac.uk/cgi-bin/targets/v5/mirna.pl?genome_id=2964) were
downloaded. These predictions combine the miRanda algorithm
and the conservation of miRNA binding sites in orthologous
transcripts from at least two species (http://microrna.sanger.ac.uk/
targets/v5/info.html for details) [76].
Biological functions of the in silico predicted miRNA
targets
We made use of the Gene Ontology (http://www.geneontology.
org), GeneCards (http://www.genecards.org/) and GeneNote
(http://bioinfo2.weizmann.ac.il/cgi-bin/genenote/home_page.pl)
databases to document the biological functions of the genes that
were predicted to be targeted by miRNAs with altered expression
in quiescent UC and CD tissues (see Table S8).
Statistical analysis
Unpaired groups of values were compared according to the
non-parametric Mann-Whitney test. Statistical significance was set
at p#0.05.
miRNA which shared closely related expression patterns were
grouped according to K-means clustering [77] computed on line
from the GenePattern Server. The specified number of clusters
was set at 20.
When supervised class (UC or CD) prediction of individual
patient’s data was tested, we used a K Nearest Neighbors
Classification algorithm with Leave-One-Out Cross-Validation
(GenePattern ‘‘KNNXValidation’’ module). The class predictor
was uniquely defined by the initial set of patients and marker
miRNAs. The classifications were tested in leave-one-out cross-
validation mode by iteratively leaving one sample out, training a
classification on the remaining data and testing on the left out
sample.
Supporting Information
Figure S1 Histological grading of disease activity in colonic
biopsies. Hematoxylin and eosin staining of biopsies from non-
inflamed and inflamed colonic mucosa (see Materials and Methods
for details on histological grading). Note the progressive loss of
intestinal epithelium with increasing grade of the disease (2–4) and
the concomitant increase in the severity of inflammation/
infiltration. Magnification, 6100.
Found at: doi:10.1371/journal.pone.0013160.s001 (0.35 MB TIF)
Figure S2 Flow chart of sample selection. In order to exclude
any bias in homogeneity among samples, biopsies of patients with
endoscopically quiescent, but histologically active colonic mucosa
were excluded. The histological dichotomy (grades 0–1 vs. 2–4)
was strictly followed to study the alteration in miRNA gene
expression. Similarly, 1 control patient with lymphocytic colitis
was excluded. In all cases, RNA preparations of low integrity
(RIN,7) were discarded.
Found at: doi:10.1371/journal.pone.0013160.s002 (0.09 MB TIF)
Figure S3 Alteration of miRNA gene expression in non-
inflamed and inflamed UC and CD tissues : Box-whisker plot
analysis of standard deviations. miRNA expression was measured
in non-inflamed and inflamed colonic mucosa obtained from
patients with UC and CD (8 patients/IBD) and computed vs. that
measured in healthy controls. The mean and standard deviation
(SDmiRNA) of relative miRNA expression were then calculated
for every miRNA, independently in each IBD for each state of the
disease. SDmiRNA were then plotted as box-whisker plots (box,
25–75%; whisker, 10–90%; line, median) (1). 1 Tukey, J. W.
(1977) in Exploratory Data Analysis (Addison-Wesley, Reading,
MA), pp. 39–43.
Found at: doi:10.1371/journal.pone.0013160.s003 (0.06 MB TIF)
Figure S4 Overview of the chromosomal distribution of miRNA
genes with altered expression in IBD tissues: The total number of
miRNA genes with altered expression was determined by
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under -expression, respectively.
Found at: doi:10.1371/journal.pone.0013160.s004 (0.10 MB TIF)
Figure S5 Alteration of miRNA gene expression in IBD tissues:
sub-chromosomal localization of the affected loci. Chromosomal
bands where 2 (arrowheads) or more (squares) miRNA genes with
altered expression colocalize are shown. Grey and light-red
symbols represent loci where IBD susceptibility has yet been
demonstrated by genetic means and previously unidentified loci,
respectively.
Found at: doi:10.1371/journal.pone.0013160.s005 (0.12 MB TIF)
Table S1 miRNA expression in left and right colon of healthy
individuals. Relative miRNA expression (106log102
,DCT; see
Materials and Methods) was calculated in the right and left colons
independently. Note that miRNA expression was similar in both
segments of the colon.
Found at: doi:10.1371/journal.pone.0013160.s006 (0.02 MB
XLS)
Table S2 Characteristics of patients with CD or UC and of
healthy control individuals. * Sex: F : female/M : male; + disease
location: C: colon/IC: ileocolonic/C+AP: colon and anoperineal
lesions/R: right colon/S: sigmoid colon/LC: left colon; # Current
treatment : CS: steroids/5 ASA: 5 aminosalicylates/AZA:
azathioprine/IFX: infliximab/MTX: methotrexate.
Found at: doi:10.1371/journal.pone.0013160.s007 (0.01 MB
XLSX)
Table S3 Alterations of miRNA expression in UC patients.
Relative miRNA expression was computed vs. that measured in
healthy controls and expressed as 106log102
2DDCT. Are only
listed the miRNAs with relative expressions .7o r,27 in non-
inflamed UC tissues. When adequate, alteration of expression in
inflamed UC is also mentioned. Access_Nu, MIMAT identifica-
tion number; Mean 6 Sem (5–8 patients). Statistical significance
(p values) was calculated relative to healthy control tissue using the
non-parametric Mann-Whitney test. Bolded, miRNA with statis-
tically significant dysregulation of expression in both quiescent and
inflamed UC.
Found at: doi:10.1371/journal.pone.0013160.s008 (0.03 MB
XLS)
Table S4 Alterations of miRNA expression in CD patients.
Relative miRNA expression was computed vs. that measured in
healthy controls and expressed as 106log102
2DDCT. Are only
listed the miRNAs with relative expressions .7o r,27 in non-
inflamed CD tissues. When adequate, alteration of expression in
inflamed CD is also mentioned. Access_Nu, MIMAT identifica-
tion number; Mean 6 Sem (5–8 patients). Statisticalsignificance (p
values) was calculated relative to healthy control tissue using the
non-parametric Mann-Whitney test. Bolded, miRNA with statis-
tically significant dysregulation of expression both in quiescent and
in inflamed CD.
Found at: doi:10.1371/journal.pone.0013160.s009 (0.04 MB
XLS)
Table S5 Shared alterations of miRNA expression in UC and
CD patients. Relative miRNA expression was computed vs. that
measured in healthy controls. miRNA with shared and significant
overexpression (106log102
2DDCT.7) both in non-inflamed UC
and in non-inflamed CD tissues are listed. Access_Nu, MIMAT
identification number; Mean 6 Sem (5–8 patients). Italics (2 lower
rows), miRNA that are not overexpressed in inflamed UC (mir-
196a) or CD (mir-30c).
Found at: doi:10.1371/journal.pone.0013160.s010 (0.02 MB
XLS)
Table S6 Compilation of the characteristics of the miRNA with
significantly altered expression in quiescent UC and CD colonic
mucosa. Access_Nu, MIMAT identification number; Gene-Id,
miRNA gene identification number; Coordinates, coordinate of
the miRNA gene on the chromosome [strand] (from http://www.
mirbase.org/cgi-bin/mirna_summary.pl?org=hsa); Band, Chro-
mosomal band where the miRNA gene is localized; Gene Context,
presence or absence (intergenic) of overlap between the miRNA
gene and another gene either on the same or on the opposite
strand.
Found at: doi:10.1371/journal.pone.0013160.s011 (0.05 MB
XLS)
Table S7 Compilation of the sub-chromosomal regions where
acknowledged IBD-susceptibility loci and miRNA genes with
altered expression colocalize. Chromosomal locations where
colocalize miRNA genes with altered expression relative to
healthy controls in quiescent and/or inflamed UC or CD tissues
and (i) acknowledged IBD susceptibility loci or (ii) replicated
sub-chromosomal regions identified in GWAS are listed. The
location of each IBD susceptibility loci is reminded. Gene_Id,
miRNA gene identification number; Locus, chromosomal band
where the miRNA gene is localized; Quiescent, non-inflamed;
Both, non-inflamed and inflamed; +/2, +: overexpression;
2: underexpression.
Found at: doi:10.1371/journal.pone.0013160.s012 (0.01 MB
XLSX)
Table S8 Alteration of miRNA expression in the colonic mucosa
of UC and CD patients: in silico characterization of target
transcripts. The exhaustive list of genes which are putatively
targeted by the subset of 8 miRNAs that share common
dysregulated overexpression in both UC and CD was downloaded
from the PITA catalog of predicted human microRNA targets
(http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html). The
algorithm makes use of the parameter-free model for miRNA-
target interaction described by Kertesz et al. (2007). Genes
involved in a common biological process are listed together. Bold
characters: strictly down regulated genes (the 39-UTR of which
interacts only with up-regulated miRNA(s))
Found at: doi:10.1371/journal.pone.0013160.s013 (0.08 MB
XLS)
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